Daily

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX): A look at Yield & Technicals With EBITDA at -0.242824

In terms of EBITDA Yield, Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) currently has a value of -0.242824. This value is derived by dividing EBITDA by Enterprise Value.

Investing in the stock market offers the potential for big returns. On the flip side, investors can also experience major losses when trading equities. Investors are typically trying their best to maximize returns while limiting losses. Figuring out the best way to do this is no easy proposition. There may be periods where everything seems to be working out, and the returns are rolling in. There may be other times when nothing seems to be going right, and the losses start to pile up. Nobody can predict with pinpoint certainty which way the market will shift in the future. Preparing the portfolio for multiple scenarios can help the investor stick it out when the waters get choppy. Having a properly diversified stock portfolio may help investors ride out the turbulence when it inevitably takes control of the market.  

Piotroski F-Score

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 1. A score of nine indicates a high value stock, while a score of one indicates a low value stock.

The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years.  The score is a number between one and one hundred (1 being best and 100 being the worst).  The Gross Margin Score of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 50.00000.  The more stable the company, the lower the score.  If a company is less stable over the course of time, they will have a higher score.

Price Index

The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) for last month was 0.98596. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 0.36894.

Another useful indicator to assist in detmining rank is the ERP5 Rank.  This is an investment tool that analysts use to discover undervalued companies.  The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC.  The ERP5 of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 18669.  The lower the ERP5 rank, the more undervalued a company is thought to be.

Looking further, the MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price.  The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital.  The MF Rank of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 17898.  A company with a low rank is considered a good company to invest in.  The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it!

This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market…

You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more. Click here to receive your Free Report immediately!

Earnings Yield

The Earnings to Price yield of Eloxx Pharmaceuticals, Inc. NASDAQ:ELOX is -0.204240. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Eloxx Pharmaceuticals, Inc. NASDAQ:ELOX is -0.243936. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is .

ROIC

The Return on Invested Capital (aka ROIC) for Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is -4.209662.  The Return on Invested Capital is a ratio that determines whether a company is profitable or not.  It tells investors how well a company is turning their capital into profits.  The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital.  The employed capital is calculated by subrating current liabilities from total assets.  Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years.  The ROIC Quality of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is .  This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC.  The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets).  The ROIC 5 year average of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is .

The Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 81.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings.  Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.  The Value Composite Two of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) is 85.

When doing stock research, there is plenty of easily measureable data regarding publically traded companies. There is also plenty of information that is not easily measured such as competitive advantage, quality of staff, and company reputation. Because there are forces such as the human element that come into play when selecting stocks, prices may not always move as expected. Even after crunching all the numbers and digging deep into a specific company, the stock’s performance still might not match expectations. Investors may realize that sometimes perception can be more powerful than reality. Human emotions can change very rapidly, and so can the prevailing market sentiment as well.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*